CrownBio has built up a strong and unique DMPK expertise team and modern equipped labs with state-of-the-art facilities with full capabilities to
- Support integrated drug discovery projects
- Provide stand-alone ADME/DMPK service
from early physicochemical property screening, in vitro ADME profiling to late in vivo PK as well as PK/PD studies from rodent to non human primates (NHP) for both small molecules and biologics.
Our service advantages include:
- High quality and complete in vitro ADME and in vivo PK package
- Experienced expertise team and strong problem-solving capacities
- GLP-like SOP, QA, QC and in-depth knowledge for data interpretation
- New technologies and cutting-edge approaches to address DMPK issues
- Small to large molecule PK in small animals to NHP (non human primates)
- Criteria and risk assessment for DDI and RM, dose, exposure and safety margin
- Cost-effective and fast turnaround using automated high-throughput technologies
- EHS-compliant environment and drug metabolism testing according to FDA guidance